SCHEMBL23976265

SCHEMBL23976265

c1ccc(-c2nc3c(c(N4CCCNCC4)n2)CCC3)nc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.48
TDP1 Q9NUW8 2/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
METAP1 P53582 2/20 0.48
MAPK1 P28482 2/20 0.48
LMNA P02545 1/20 0.48
TSHR P16473 1/20 0.48
KMT2A Q03164 1/20 0.48
CFTR P13569 6/20 0.45
HTR7 P34969 2/20 0.44
MAPT P10636 1/20 0.42
PPP1CA P62136 1/20 0.42
HIF1A Q16665 1/20 0.42
HTR1A P08908 1/20 0.42
HRH4 Q9H3N8 1/20 0.42
PRKCI P41743 3/20 0.41
ROCK2 O75116 1/20 0.41
ROCK1 Q13464 1/20 0.41
ALOX15 P16050 1/20 0.41
PLD1 Q13393 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23975644 0.88 TDP1 (0.61) RAB9ATDP1L3MBTL1METAP1MAPK1
SCHEMBL10150244 0.87 RAB9A (0.59) RAB9ATDP1L3MBTL1METAP1MAPK1
SCHEMBL30302475 0.86 RAB9A (0.61) RAB9ATDP1L3MBTL1METAP1MAPK1
SCHEMBL10150248 0.86 RAB9A (0.61) RAB9ATDP1L3MBTL1METAP1MAPK1
SCHEMBL23975767 0.84 RAB9A (0.44) RAB9ATDP1L3MBTL1METAP1MAPK1
SCHEMBL23975624 0.84 CFTR (0.45) RAB9ATDP1L3MBTL1METAP1MAPK1
SCHEMBL23976131 0.83 RAB9A (0.49) RAB9ATDP1L3MBTL1METAP1MAPK1
SCHEMBL23986868 0.82 CFTR (0.52) RAB9ATDP1L3MBTL1METAP1MAPK1
SCHEMBL23975643 0.82 METAP1 (0.61) RAB9ATDP1L3MBTL1METAP1MAPK1
SCHEMBL23975713 0.82 HIF1A (0.53) RAB9ATDP1L3MBTL1METAP1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11746100-B2 Cycloalkyl pyrimidines as ferroportin inhibitors GLOBAL BLOOD THERAPEUTICS, INC. (US) 2023-09-05 US disclosed
US-11746100-B2 Cycloalkyl pyrimidines as ferroportin inhibitors GLOBAL BLOOD THERAPEUTICS, INC. (US) 2023-09-05 US disclosed
US-20230226074-A1 METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS GLOBAL BLOOD THERAPEUTICS INC (US) 2023-07-20 US disclosed
US-20230226074-A1 METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS GLOBAL BLOOD THERAPEUTICS INC (US) 2023-07-20 US disclosed
US-20220396562-A1 CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. 2022-12-15 US disclosed
WO-2021222483-A1 METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. (US) 2021-11-04 WO disclosed
WO-2021222363-A1 CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. (US) 2021-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230226074-A1 METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS SLC40A1, HAMP, SLC19A1 RAB9A 2710/4885TDP1 1304/4885L3MBTL1 3327/4885
US-11746100-B2 Cycloalkyl pyrimidines as ferroportin inhibitors HAMP, SLC40A1, FANCI RAB9A 2831/4885TDP1 2891/4885L3MBTL1 3035/4885
US-20220396562-A1 CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS HAMP, SLC40A1, FANCI RAB9A 2831/4885TDP1 2891/4885L3MBTL1 3035/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.